Skip to main content
AllCereno Scientific

Cereno Scientific terminates agreement with liquidity provider

By December 22, 2020No Comments

TUE, DEC 22, 2020 16:30 CET

Cereno Scientific announced today that the agreement with Mangold Fondkommission to act as liquidity provider for the company’s share has been terminated. The share has a good spread and a liquidity provider is therefore no longer needed. The assignment will end on December 29, 2020, without a new liquidity provider agreement replacing the previous commitment.

For further information, please contact:
Daniel Brodén, CFO
Tel: +46 768 66 77 87

About Cereno Scientific AB
Cereno Scientific is a leading clinical stage biotech company within cardiovascular epigenetic modulation. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. A clinical phase II study program for CS1 in PAH is planned to start mid-2021 under its US FDA granted orphan drug designation (ODD) status. In addition, Cereno has a preclinical HDAC inhibitor development program targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has an office in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on